Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects
| Autor: | H.C. Geiss, Carsten Otto, Klaus G. Parhofer, Peter Schwandt |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Male
Hyperlipoproteinemias medicine.medical_specialty Endocrinology Diabetes and Metabolism Atorvastatin chemistry.chemical_compound Endocrinology Internal medicine Blood plasma medicine Humans Pyrroles Triglyceride Cholesterol Middle Aged Hydroxymethylglutaryl-CoA reductase Lipoproteins LDL Diabetes Mellitus Type 2 chemistry Heptanoic Acids Case-Control Studies Low-density lipoprotein Female lipids (amino acids peptides and proteins) Density gradient ultracentrifugation Hydroxymethylglutaryl-CoA Reductase Inhibitors Lipoprotein medicine.drug |
| Zdroj: | Metabolism. 50:983-988 |
| ISSN: | 0026-0495 |
| DOI: | 10.1053/meta.2001.24879 |
| Popis: | Atorvastatin is a potent hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor that decreases low-density lipoprotein (LDL) cholesterol and triglyceride concentrations, but little is known about its effects on LDL subtype distribution in different types of hyperlipoproteinemia. Thus, we evaluated the influence of atorvastatin (10 mg/d, 4 weeks) on lipid concentrations and LDL subtype distribution in patients with hypercholesterolemia (n = 9; LDL cholesterol, 227 +/- 30 mg/dL; triglycerides, 137 +/- 56 mg/dL), patients with type 2 diabetes and dyslipoproteinemia (n = 11; LDL cholesterol, 163 +/- 34 mg/dL; triglycerides, 260 +/- 147 mg/dL), and controls (n = 10; LDL cholesterol, 116 +/- 20 mg/dL; triglycerides, 130 +/- 47 mg/dL). Cholesterol concentration was determined in 7 LDL subfractions isolated by density gradient ultracentrifugation before and during atorvastatin treatment. Atorvastatin decreased LDL cholesterol (-36%, -28%, and -41%, all P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect